RxDoctor Payments Data

Donald Liebelt, MD

Family Medicine · Ocala, FLNPI 1710969076

Payments from drug & device makers

$2,789in general payments, 2019–2025

Across 140 payments — averaging $19.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$692
  • Johnson & Johnson$363
  • AstraZeneca$293
  • GSK$282
  • Amarin Pharma, Inc.$151
  • Boehringer Ingelheim$148
  • plus $859 from 18 others

What the payments were for

  • Food & beverage$2,74398%
  • Education$462%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,789 in reported general payments places this provider in the 80th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$208,001
Medicare patients
466
Services billed
2,673

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide54$60,691
EliquisApixaban50$57,235
JardianceEmpagliflozin40$44,104
XareltoRivaroxaban14$22,670
RybelsusSemaglutide15$16,369
MounjaroTirzepatide11$11,536
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$7,323
Atorvastatin Calcium323$3,249
Omeprazole179$2,469
Levothyroxine Sodium245$2,267
Gabapentin89$2,003
Losartan Potassium177$1,847
Celecoxib18$1,723
Rosuvastatin Calcium188$1,700
Amlodipine Besylate226$1,662

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$692$77,06069 claims
PfizerEliquis$80$57,23550 claims
Boehringer IngelheimJardiance$148$44,10440 claims
Johnson & JohnsonXarelto$363$22,67014 claims
Lilly USA, LLCMounjaro$145$11,53611 claims
GSKTrelegy Ellipta$282$7,32311 claims
AbbVieSynthroid$134$1,57834 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Ocala

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →